Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Cancer Drug Efficacy Triggers Early Phase III Trial Termination

This article was originally published in The Pink Sheet Daily

Executive Summary

Angiogenesis inhibitor SU11248 shows significant efficacy in Gleevec-resistant gastrointestinal stromal tumors; Pfizer plans NDA submission for GIST and renal cell carcinoma by end of 2005. A Phase III trial in second-line renal cell carcinoma is ongoing.

You may also be interested in...



Filing Timeline Unclear After Sutent Trial In Rare Pancreatic Cancer Stops Early

Phase III study, halted for efficacy, tested the tyrosine kinase inhibitor in a disease type that strikes about 30 to 50 patients per million of the total afflicted.

Filing Timeline Unclear After Sutent Trial In Rare Pancreatic Cancer Stops Early

Phase III study, halted for efficacy, tested the tyrosine kinase inhibitor in a disease type that strikes about 30 to 50 patients per million of the total afflicted.

Sutent Shows Benefit In Rare Pancreatic Cancer; Pfizer Stops Phase III Early

Pfizer stopped a Phase III trial for its cancer drug Sutent (sunitinib) early after the data safety monitoring board said the compound showed significant benefit in a rare form of pancreatic cancer, the company announced March 12

Topics

UsernamePublicRestriction

Register

PS061688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel